Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

NeuroPace, Inc.

NPCENASDAQ
Healthcare
Medical - Devices
$14.56
$0.22(1.53%)
U.S. Market opens in 16h 13m

NeuroPace, Inc. Fundamental Analysis

NeuroPace, Inc. (NPCE) shows moderate financial fundamentals with a PE ratio of -19.83, profit margin of -25.28%, and ROE of -1.37%. The company generates $0.1B in annual revenue with strong year-over-year growth of 22.14%.

Key Strengths

Cash Position12.44%
PEG Ratio-2.08
Current Ratio4.86

Areas of Concern

ROE-1.37%
Operating Margin-19.21%
We analyze NPCE's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -126.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-126.3/100

We analyze NPCE's fundamental strength across five key dimensions:

Efficiency Score

Weak

NPCE struggles to generate sufficient returns from assets.

ROA > 10%
-22.36%

Valuation Score

Excellent

NPCE trades at attractive valuation levels.

PE < 25
-19.83
PEG Ratio < 2
-2.08

Growth Score

Excellent

NPCE delivers strong and consistent growth momentum.

Revenue Growth > 5%
22.14%
EPS Growth > 10%
26.77%

Financial Health Score

Moderate

NPCE shows balanced financial health with some risks.

Debt/Equity < 1
3.84
Current Ratio > 1
4.86

Profitability Score

Weak

NPCE struggles to sustain strong margins.

ROE > 15%
-136.60%
Net Margin ≥ 15%
-25.28%
Positive Free Cash Flow
No

Key Financial Metrics

Is NPCE Expensive or Cheap?

P/E Ratio

NPCE trades at -19.83 times earnings. This suggests potential undervaluation.

-19.83

PEG Ratio

When adjusting for growth, NPCE's PEG of -2.08 indicates potential undervaluation.

-2.08

Price to Book

The market values NeuroPace, Inc. at 25.69 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

25.69

EV/EBITDA

Enterprise value stands at -28.21 times EBITDA. This is generally considered low.

-28.21

How Well Does NPCE Make Money?

Net Profit Margin

For every $100 in sales, NeuroPace, Inc. keeps $-25.28 as profit after all expenses.

-25.28%

Operating Margin

Core operations generate -19.21 in profit for every $100 in revenue, before interest and taxes.

-19.21%

ROE

Management delivers $-1.37 in profit for every $100 of shareholder equity.

-1.37%

ROA

NeuroPace, Inc. generates $-22.36 in profit for every $100 in assets, demonstrating efficient asset deployment.

-22.36%

Following the Money - Real Cash Generation

Operating Cash Flow

NeuroPace, Inc. generates limited operating cash flow of $-16.39M, signaling weaker underlying cash strength.

$-16.39M

Free Cash Flow

NeuroPace, Inc. generates weak or negative free cash flow of $-16.67M, restricting financial flexibility.

$-16.67M

FCF Per Share

Each share generates $-0.50 in free cash annually.

$-0.50

FCF Yield

NPCE converts -3.47% of its market value into free cash.

-3.47%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-19.83

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.08

vs 25 benchmark

P/B Ratio

Price to book value ratio

25.69

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.04

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

3.84

vs 25 benchmark

Current Ratio

Current assets to current liabilities

4.86

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.37

vs 25 benchmark

ROA

Return on assets percentage

-0.22

vs 25 benchmark

ROCE

Return on capital employed

-0.21

vs 25 benchmark

How NPCE Stacks Against Its Sector Peers

MetricNPCE ValueSector AveragePerformance
P/E Ratio-19.8329.43 Better (Cheaper)
ROE-136.60%800.00% Weak
Net Margin-25.28%-20145.00% (disorted) Weak
Debt/Equity3.840.30 Weak (High Leverage)
Current Ratio4.864.64 Strong Liquidity
ROA-22.36%-17936.00% (disorted) Weak

NPCE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NeuroPace, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-17.61%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

65.48%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

72.66%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ